icon-folder.gif   Conference Reports for NATAP  
  EASL - The International Liver Congress 2014
49th Annual Meeting of the European
Association for the Study of the Liver
London, United Kingdom  April 9-13
Back grey_arrow_rt.gif
Comorbidities Associated with Not Being Treated for HCV
  Reported by Jules Levin
EASL 2014
In light of the restrictions some state medicaid are placing on patients with HCV here is an interesting study. As well some state medicaids are not allowing individuals with evidence of substance abuse in the past 12 or 6 months to access the new HCV treatments which is harsh & punitive because injection drug use is the highest cause for HCV transmission, and to deny this patient population access to treatment is too harsh & punitive and serves to increase rates of transmission, treatment & cure for IDUS can only serve to reduce transmission. These state medicaids are very self-serving.
Comorbid Conditions Associated With Decision-Making Regarding Treating or Not Treating Chronic Hepatitis C In A Large U.S. Health Maintenance Organization - (04/17/14)
In this retrospective study using data from Kaiser Permanente, Southern California, a large Health Maintenance Organization including 3.5 - 4 million members
many patients have not been treated previously with Peg/Rbv therapy:
the study reported-
50% (16,186/32,283) of the study population had a significant comorbid illness
-15% (2,484/16,186) were treated
-85% (13,702/16,186) were not treated

Comorbid illness: Anemia, Autoimmune disorder, Renal dysfunction, CVD, Psychosis/Bipolar, Severe lung disease, Substance abuse, Hepatitis B, MELD ≥ 12